EMERYVILLE, Calif., June 20, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for its autologous, fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of stiff-person syndrome (SPS) in Kyverna's trial, named KYSA-8.
The “remarkable” success of chimeric antigen receptor T-cell therapy (CAR-T) in lupus has led to a gold rush as cell therapy companies shift their focus from oncology to immunology. But a new relapse in a clinical trial may dim the strategy’s glow, at least in the eyes of investors.
EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting on April 13.
Kyverna Provides Business Update and Reports FY23 Financial Results
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101
Kyverna CEO Peter Maag, Ph.D., was unequivocal when asked how it feels to be one of biotech’s torchbearers for autoimmune-focused cell therapies.
Apparently Kyverna Therapeutics wasn’t getting carried away when it raised its IPO expectations on Tuesday.
Kyverna Therapeutics is looking to capitalize on a more healthy public marketplace, boosting estimates for its IPO haul by around $100 million.